Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Chinese Clinical Oncology|September 2, 2025
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative reviewFabrizio Di Costanzo, Iolanda Santa Parisi, Giuseppe Neola, et al.
Urologia Internationalis|November 18, 2025
Impact of Body Mass Index on Renal Function Impairment in Patients Treated for Renal Cell Carcinoma at High Risk of Recurrence: Key Implications for Systemic Therapy EligibilityPietro Scilipoti, Giuseppe Rosiello, Mattia Longoni, et al.
Clinical Genitourinary Cancer|July 19, 2024
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal CancerMarzia Del Re, Stefania Crucitta, Nicole Brighi, et al.
World Journal of Urology|November 8, 2025
Impact of timing between neoadjuvant therapy and radical cystectomy on survival in muscle-invasive bladder cancerPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
BJU International|October 7, 2023
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancerAndrea Necchi, Giuseppe Basile, Ewan A Gibb, et al.
The Lancet. Oncology|March 2, 2026
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 studyAndrea Necchi, Brigida A Maiorano, Joep J de Jong, et al.
JCO Precision Oncology|December 3, 2024
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic ReviewEmanuele Crupi, Tiago Costa de Padua, Laura Marandino, et al.
The Oncologist|November 17, 2025
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysisFabrizio Di Costanzo, Chiara Mercinelli, Alessio Signori, et al.
Radiology|December 24, 2024
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRIGiorgio Brembilla, Giuseppe Basile, Michele Cosenza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder CancerChiara Mercinelli, Marco Moschini, Antonio Cigliola, et al.
Pageof 5